Literature DB >> 28471246

Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results.

Peter P Toth1,2, Warren Stevens3, Jacquelyn W Chou3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28471246     DOI： 10.1080/13696998.2017.1327440

Source DB:  PubMed          Journal:  J Med Econ        ISSN： 1369-6998            Impact factor:   2.448


× No keyword cloud information.
  2 in total

1.  Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease.

Authors:  Alanna M Chamberlain; Sarah S Cohen; Susan A Weston; Kathleen M Fox; Pin Xiang; Jill M Killian; Yi Qian
Journal:  Am J Cardiol       Date:  2019-03-08       Impact factor: 2.778

2.  PCSK9 Inhibitors Show Value for Patients and the US Health Care System.

Authors:  Wei-Han Cheng; Étienne Gaudette; Dana P Goldman
Journal:  Value Health       Date:  2017-06-17       Impact factor: 5.725
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.